PB0418 - Lack of Clinically Significant Hepatotoxicity in Patients with ChronicImmune Thrombocytopenia (c-ITP) Treated with the Novel, OralThrombopoietin Receptor Agonist Avatrombopag-pooled Safety Analysis ofFour Clinical TrialsJ. Bussel1, L.F. Allen2, K. Aggarwal2, M. Vredenburg2, W. Tian2, H.Liebman3 1Weill Cornell Medical College, New York, United States, 2DovaPharmaceuticals, Durham, United States, 3USC Keck School of Medicine, LosAngeles, United StatesBackground: Thrombopoietin receptor ag...